HomeCompareLAXXW vs ABBV

LAXXW vs ABBV: Dividend Comparison 2026

LAXXW yields 1024.07% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LAXXW wins by $23192664.72M in total portfolio value
10 years
LAXXW
LAXXW
● Live price
1024.07%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23192664.83M
Annual income
$19,455,426,598,308.32
Full LAXXW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LAXXW vs ABBV

📍 LAXXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLAXXWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LAXXW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LAXXW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LAXXW
Annual income on $10K today (after 15% tax)
$87,045.57/yr
After 10yr DRIP, annual income (after tax)
$16,537,112,608,562.07/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LAXXW beats the other by $16,537,112,587,506.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LAXXW + ABBV for your $10,000?

LAXXW: 50%ABBV: 50%
100% ABBV50/50100% LAXXW
Portfolio after 10yr
$11596332.46M
Annual income
$9,727,713,311,540.04/yr
Blended yield
83.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LAXXW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LAXXW buys
0
ABBV buys
0
No recent congressional trades found for LAXXW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLAXXWABBV
Forward yield1024.07%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$23192664.83M$102.3K
Annual income after 10y$19,455,426,598,308.32$24,771.77
Total dividends collected$22908054.02M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LAXXW vs ABBV ($10,000, DRIP)

YearLAXXW PortfolioLAXXW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$113,107$102,406.55$11,550$430.00+$101.6KLAXXW
2$1,203,534$1,082,509.57$13,472$627.96+$1.19MLAXXW
3$12,052,889$10,765,108.50$15,906$926.08+$12.04MLAXXW
4$113,651,820$100,755,228.43$19,071$1,382.55+$113.63MLAXXW
5$1,009,517,631$887,910,183.49$23,302$2,095.81+$1009.49MLAXXW
6$8,451,122,102$7,370,938,237.25$29,150$3,237.93+$8451.09MLAXXW
7$66,711,307,874$57,668,607,224.67$37,536$5,121.41+$66711.27MLAXXW
8$496,823,493,276$425,442,393,850.45$50,079$8,338.38+$496823.44MLAXXW
9$3,492,746,006,709$2,961,144,868,903.27$69,753$14,065.80+$3492745.94MLAXXW
10$23,192,664,825,486$19,455,426,598,308.32$102,337$24,771.77+$23192664.72MLAXXW

LAXXW vs ABBV: Complete Analysis 2026

LAXXWStock

LAXXW is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in LAXXW shares.

Full LAXXW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LAXXW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LAXXW vs SCHDLAXXW vs JEPILAXXW vs OLAXXW vs KOLAXXW vs MAINLAXXW vs JNJLAXXW vs MRKLAXXW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.